rheumatoid arthritis
Conditions
Interventions
Gold Standard:?Western diagnostic criteria for seropositive rheumatoid arthritis: The RA classification criteria of ACR/EULAR in 2010 were used for comprehensive judgment, and serum RF and/or ACPAs we
? Western diagnostic criteria for sero-negative rheumatoid arthritis: RA classification criteria of ACR/EULAR in 2010 were used for comprehensive judgment, and serum RF and ACPAs were negative
?Western diagnostic criteria for hand osteoarthritis: refer to the diagnostic criteria for hand OA revised by ACR in 1995.
Index test:This study is a cross-sectional study and involve no drug treatment or outcome index observation.
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Study subjects should meet the following diagnostic criteria: Western diagnostic criteria for seropositive rheumatoid arthritis: The RA classification criteria of ACR/EULAR in 2010 were used for comprehensive judgment, and serum RF and/or ACPAs were positive; (2) Western diagnostic criteria for sero-negative rheumatoid arthritis: RA classification criteria of ACR/EULAR in 2010 were used for comprehensive judgment, and serum RF and ACPAs were negative; ? Western diagnostic criteria for hand osteoarthritis: refer to the diagnostic criteria for hand OA revised by ACR in 1995; (2) Aged 18-75 years; (3) Written informed consent signed by the subject or his family (guardian) agreeing to participate in the study.
Exclusion criteria
Exclusion criteria: Potential subjects meeting the inclusion criteria will be excluded if they meet any of the following criteria: (1) those who have used hormones in the past 3 months or are currently using them; (2) Patients who had used tripterygium glycosides, leflunomide, hydroxychloroquine, salazopyridine, penicillamine and other anti-rheumatic drugs within 1 month; (3) previous or current use of biological agents; (4) combined with other rheumatic diseases; (5) complicated with tumors, serious cardiovascular and cerebrovascular diseases, liver and kidney, hematopoietic system diseases and mental disorders; (6) High fever, tuberculosis, acute suppurative and other infectious diseases; (7) Pregnant, lactating or menstruating women; (8) Patients whom the clinician deems inappropriate to participate in this clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| proteomics analysis;Metabolomics analysis;Immune repertoire analysis;Transcriptomic analysis;Multi-omics association integration analysis; | — |
Countries
China
Contacts
Public ContactXiumin Chen
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed